Recent successful drug launches indicate a trend toward more specialized, high-priced drugs that treat less-common medical conditions.
The post Conclusions We Can Draw from Recent Successful Drug Launches appeared first on DrugPatentWatch – Make Better…
Conclusions We Can Draw from Recent Successful Drug Launches Read Post »
Pharmaceutical formulary managers have a pressing need to manage their formulary budgets. Anticipating when drugs will face loss-of-exclusivity — when their key patents will expire — is an essential first-step…
The post Pharmaceutical Formulary Managem…
This paper was originally published by Jian Du, Peixin Li, Qianying Guo, and Xiaoli Tang at Journal of Informetrics Volume 13, Issue 1, February 2019, Pages 132-148 under a a Creative Commons license.…
The post Measuring the knowledge translation and c…
Prescription drugs are expensive to develop, and many intermediaries stand between patients and drug makers. Here’s where the money goes.
The post Drug Spending in the US: Where the Money Actually Goes appeared first on DrugPatentWatch – Make Better De…
Drug Spending in the US: Where the Money Actually Goes Read Post »
Businessman and investor Mark Cuban is probably best known as the owner of the Dallas Mavericks and as an investor on the reality television series Shark Tank. His business and…
The post Mark Cuban Unexpected Leader in Orphan Drug Development Reform ap…
Mark Cuban Unexpected Leader in Orphan Drug Development Reform Read Post »
Anticipate the Future Global biopharmaceutical markets face constant change. To remain competitive you need to anticipate what’s next. We understand and work together with you to help you make better…
The post Helping You Make Better Decisions: The Dru…
Helping You Make Better Decisions: The DrugPatentWatch Design Philosophy Read Post »
Partner With DrugPatentWatch Become a Data Integration Partner DrugPatentWatch’s Data Integration Program is for companies that want to better serve their clients by building an integration between their technology and…
The post Partner With DrugPatent…
The average time to market for a new drug is around 12 years, at a cost averaging $2.6 billion, according to 2014 research by Tufts University. And there’s no indication that…
The post How AI Is Already Changing Drug Development appeared first on DrugP…
By Nanette Moss, S.M., C.I.H., Senior Scientist and Project Executive with Environmental Health & Engineering, Inc. What is business continuity planning and why it is important? Emergencies may be infrequent…
The post Business Continuity and Resiliency…
Business Continuity and Resiliency Planning for Biomedical and Research Organizations Read Post »
In November 2018, the Government Accountability Office (GAO) released a report titled “FDA Could Improve Designation Review Consistency; Rare Disease Drug Development Challenges Continue.” It follows up on the FDA’s Orphan…
The post Key Findings from G…
Key Findings from GAO Report on Orphan Drug Approval Modernization Read Post »